United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

Posted by George Bondi on Oct 20th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $543.32, for a total transaction of $5,161,540.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $176,276,370.76. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

UTHR traded up $10.73 on Tuesday, reaching $553.88. The company had a trading volume of 437,754 shares, compared to its average volume of 556,374. The stock has a market cap of $23.76 billion, a P/E ratio of 19.82, a P/E/G ratio of 3.81 and a beta of 0.49. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The company’s fifty day moving average is $513.91 and its 200 day moving average is $539.71.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the company posted $6.41 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.40 EPS for the current year.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics opened its third designated pathogen-free xenograft production facility in Houston, Texas. The added capacity supports the company’s organ-manufacturing and xenotransplantation strategy, potentially improving its ability to advance and scale its transplant programs. United Therapeutics opens third xenograft production facility in Houston
Positive Sentiment: The FDA cleared United Therapeutics to proceed with the SUMMIT clinical study of treprostinil SMI in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The regulatory clearance advances a potential expansion of the company’s pulmonary-hypertension franchise, although the therapy still must demonstrate efficacy and safety in the trial. FDA Clears United Therapeutics’ SUMMIT Study of Treprostinil SMI in PH-COPD
Positive Sentiment: Leerink Partners raised its United Therapeutics price target to $725 from $685 and maintained an “outperform” rating, reinforcing the view that the company’s pipeline and commercial portfolio have additional upside. Leerink Partners raises United Therapeutics price target

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $450,140,000. Bank of New York Mellon Corp bought a new position in United Therapeutics in the second quarter valued at approximately $159,522,000. Caisse de depot et placement du Quebec acquired a new position in United Therapeutics during the second quarter valued at approximately $154,304,000. Finally, Legal & General Group Plc acquired a new position in United Therapeutics during the second quarter valued at approximately $112,209,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Leerink Partners upped their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. raised their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 price objective on shares of United Therapeutics in a research note on Thursday, October 15th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 14th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $651.21.

Read Our Latest Analysis on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.